Please login to the form below

Not currently logged in
Email:
Password:

NTDT

This page shows the latest NTDT news and features for those working in and with pharma, biotech and healthcare.

Novartis' Exjade gets EU approval for thalassaemia

Novartis' Exjade gets EU approval for thalassaemia

Novartis' Exjade (deferasirox) has received European approval as a treatment for non-transfusion-dependent thalassaemia (NTDT) syndromes, a group of genetic disorders characterised by red blood cell problems and anaemia. ... This approval is a critical

Latest news

  • CHMP backs Novartis' Bexsero, Exjade CHMP backs Novartis' Bexsero, Exjade

    It was approved in Europe in March, 2010. Thalassaemia candidate. Meanwhile, the CHMP also gave its backing to Novartis' Exjade (deferasirox) as a treatment for non-transfusion-dependent thalassaemia (NTDT) syndromes, ... Clinical trials have shown

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics